Cancer Cachexia - Pipeline Insight, 2024

This “Cancer Cachexia - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Cancer Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cancer Cachexia: Understanding

Cancer Cachexia: Overview

Cancer cachexia is an insidious syndrome that not only has a dramatic impact on patient quality of life, but is also associated with poor responses to chemotherapy and survival. Indeed, cachexia occurs in the majority of terminal cancer patients and, according to Warren, It is responsible for the death of 22% of cancer patients. It is a type of (wasting syndrome) a common complication of cancer that causes significant amounts of skeletal muscle and body fat loss.

Cancer cachexia can affect your quality of life and may affect the ability to receive cancer treatment. Its prevalence varies across cancer types, ranging from 87% in pancreatic and gastric cancer to 40% in breast cancer, sarcoma, leukemia, and Hodgkin lymphoma. As a secondary disease in cancer patients, cachexia progresses with systemic inflammation, negative protein-energy balance, and involuntary loss of lean body mass. These changes, accompanied by alterations in body composition, contribute to clinical manifestations such as significant weight reduction and disruptions in biological balance. Recognizing these symptoms is crucial for early intervention and management to improve patient outcomes.

Diagnosis typically involves assessing clinical signs such as weight loss exceeding 5% within six months, decreased food intake, reduced muscle strength, and overall decline in functional status. Laboratory tests may reveal abnormalities such as anemia, elevated inflammatory markers, and altered metabolic parameters. Imaging studies can identify tumor burden and potential complications. Importantly, diagnosis requires ruling out other causes of weight loss and muscle wasting. Once diagnosed, management involves a multidisciplinary approach focusing on symptom management, nutritional support, physical activity, and addressing underlying cancer pathology, aiming to improve quality of life and potentially treatment outcomes.

The treatment of cancer cachexia requires a comprehensive, individualized approach focused on improving muscle mass, enhancing overall body state, and increasing tolerance to anti-tumor therapies. While tumors continue to grow, cancer cachexia can be separated from underlying diseases through targeted blockade of cachexia signals, prolonging survival. Palliative treatment strategies are preferred for end-stage cachexia. In cases of catabolically active underlying diseases like advanced lung cancer and bile duct cancer, inhibiting catabolic drugs is the primary treatment choice. 

"Cancer Cachexia- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cancer Cachexia pipeline landscape is provided which includes the disease overview and Cancer Cachexia treatment guidelines. The assessment part of the report embraces, in depth Cancer Cachexia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cancer Cachexia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cancer Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cancer Cachexia.

Cancer Cachexia Emerging Drugs Chapters

This segment of the Cancer Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cancer Cachexia Emerging Drugs

• ACM-001.1: Actimed Therapeutics Ltd

S-pindolol has been described as an anabolic/catabolic transforming agent, or ACTA. S-pindolol (ACM-001) is an anabolic/catabolic transforming agent with a multifunctional effect on three key pharmacological targets relevant for cancer cachexia: (1) Reduction of catabolism by β-1 receptor antagonism, (2) Increased anabolism and muscle growth, through partial β2 receptor agonism, (3) Improvement in appetite and fatigue via central 5-HT1a antagonism. Currently, the drug is in Phase II/III stage of its clinical trial for the treatment of Cancer Cachexia.

• Ponsegromab: Pfizer

It is a monoclonal antibody directed against the human growth differentiation factor 15 (GDF15; MIC-1), with potential anti-cachexia activity. Upon administration, ponsegromab targets and binds to GDF15, thereby preventing the binding of GDF15 to its receptor glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL) and blocking GDF15/GFRAL-mediated signaling. This may abrogate loss of appetite and uncontrolled weight loss associated with high serum levels of GDF15. GDF15, a stress response cytokine and divergent member of the transforming growth factor beta (TGF-beta) superfamily, plays a key role in the regulation of body weight through central mechanisms. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Cancer Cachexia.

• AV-380: AVEO Pharmaceuticals, Inc.

AV-380 is AVEO’s first-in-class, potent, humanized inhibitory IgG1 antibody targeting growth differentiation factor 15 (GDF15). GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro-inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions. Currently, the drug is in the Phase I stage of development to treat Cancer Cachexia.

Cancer Cachexia: Therapeutic Assessment

This segment of the report provides insights about the different Cancer Cachexia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cancer Cachexia

• There are approx. 12+ key companies which are developing the therapies for Cancer Cachexia. The companies which have their Cancer Cachexia drug candidates in the most advanced stage, i.e. Phase II/III include, Actimed Therapeutics Ltd.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cancer Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cancer Cachexia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Cachexia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Cachexia drugs.

Cancer Cachexia Report Insights

• Cancer Cachexia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cancer Cachexia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cancer Cachexia drugs?
• How many Cancer Cachexia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cancer Cachexia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cancer Cachexia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cancer Cachexia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Actimed Therapeutics Ltd
• Pfizer
• AVEO Pharmaceuticals, Inc.
• NGM Biopharmaceuticals
• Endevica Bio

Key Products

• ACM-001.1
• Ponsegromab
• AV-380
• NGM120
• TCMCB07

This product will be delivered within 2 business days.